Budapest, 14th June 2018. Industry leaders from the generic, biosimilar and value added medicines industries discuss challenges and opportunities in ensuring sustainable, worldwide patient access to pharmaceuticals. Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) join forces to tackle challenges such as market sustainability, medicines shortages, and international regulatory cooperation. Opportunities can be pursued with strong stakeholder collaboration for a sustainable industry. These include the introduction of an EU SPC manufacturing waiver, and ensuring that generic, biosimilar and value added medicines can play their role in providing better access for better health.
Tokyo, Japan (June 7, 2018) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to elect the IGBA as an Management Committee Member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
February 01 2018 - Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck. Access to well-referenced information is fundamental to improving worldwide understanding and acceptance of biosimilar medicines, which support patient access to life-saving treatments, enhance competition and contribute to healthcare system sustainability by offering savings for the same medical outcome.
- IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance
- IGBA welcomes new member Indian Pharmaceutical Alliance (IPA)!
- The IGBA Biosimilars Committee has developed a communication slide deck on biosimilar medicines
- Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee